Quarterly Results
PYPD Earnings Forecast
Looking ahead, PYPD remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of undefined and an EPS of -0.33.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been No Change by 0%, while EPS estimates have been Revise Downward by -14.85%. For the upcoming Q2 2026, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a 47.30% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in PYPD long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency:

No data
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how PYPD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PYPD sees a +6.58% change in stock price 10 days leading up to the earnings, and a -1.11% change 10 days following the report. On the earnings day itself, the stock moves by -3.35%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -4.53% on the day following the earnings release and then changed by 1.33% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of PYPD's latest earnings report for FY2025Q3?
PYPD reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of 3.40M, resulting in a -100% surprise. The EPS was -0.37, surpassing the expected -0.54 by 31.48% . The stock experienced a -0.27% price change on the earnings day and a -3.32% change over the next five days, reflecting market reactions to the results.
How did PYPD's stock price react after the FY2025Q3 earnings release?
Following PYPD's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -0.27% on the day of the release. Over the subsequent five days, it saw a -3.32% change. Historically, PYPD's stock price tends to shift by an average of +6.58% in the 10 days leading up to earnings and -1.11% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for PYPD for undefined?
For , analysts estimate PYPD’s annual revenue to reach undefined, while the EPS is projected at -0.33. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.
How does PYPD's stock price correlate with earnings forecast revisions?
The correlation between PYPD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from PYPD's next earnings report?
Based on historical trends, PYPD's stock price typically moves by +6.58% in the 10 days before its earnings and -1.11% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.33 and revenue of undefined.
What is the sentiment in PolyPid Ltd (PYPD) Q3 2025 Earnings Call Summary?
The earnings call highlights positive developments like successful inspections, strong market interest, and strategic partnerships. Despite increased expenses, the company shows financial improvement and a strong cash position. The Q&A reveals confidence in FDA processes and pricing strategies. The market opportunity for D-PLEX100 is significant, with plans for expansion and premium pricing potential. While some details were unclear, the overall sentiment is positive, suggesting potential stock price growth in the short term.

